Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 16/20 | 0.39 |
| ▸ | HTR2A | P28223 | 15/20 | 0.39 |
| ▸ | HTR2B | P41595 | 11/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015013 | 1.00 | MLNR (0.40) | MLNRCYP2D6HTR2CHTR2AHTR2B | |
| SCHEMBL4009415 | 1.00 | MLNR (0.40) | MLNRCYP2D6HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL4202159 | 0.99 | MLNR (0.39) | MLNRCYP2D6HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL4206680 | 0.99 | MLNR (0.39) | MLNRCYP2D6HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL4207560 | 0.99 | MLNR (0.39) | MLNRCYP2D6HTR2CHTR2AHTR2B | |
| SCHEMBL4012389 | 0.95 | HTR2C (0.38) | MLNRCYP2D6HTR2CHTR2AHTR2B | |
| SCHEMBL4012411 | 0.95 | HTR2C (0.38) | MLNRCYP2D6HTR2CHTR2AHTR2B | |
| SCHEMBL4211245 | 0.95 | HTR2C (0.38) | MLNRCYP2D6HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL4199758 | 0.94 | HTR2C (0.37) | MLNRCYP2D6HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL4205678 | 0.94 | HTR2C (0.37) | MLNRCYP2D6HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | claimed |
| EP-2094695-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | Cascade Therapeutics Inc. (CA) | 2009-09-02 | — | — | EP | claimed |
| WO-2009079765-A1 | COMPOUNDS WITH ACTIVITY AT THE 5-HT2C RECEPTOR | CASCADE THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | WO | claimed |
| WO-2008009125-A9 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | NPS ALLELIX CORP (CA) | 2008-07-24 | — | — | WO | claimed |
| WO-2008009125-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | claimed |
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| EP-2094695-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | Cascade Therapeutics Inc. (CA) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009079765-A1 | COMPOUNDS WITH ACTIVITY AT THE 5-HT2C RECEPTOR | CASCADE THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008009125-A9 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | NPS ALLELIX CORP (CA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008009125-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | HTR2C, HTR2A, HTR5A | MLNR 261/4885CYP2D6 594/4885HTR2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.